Abstract:Pediatric brain tumors are the second most common malignancy of childhood after acute leukemia and the number one cause of cancer-related mortality1. Over the past decade, advanced molecular diagnostics have led to the discovery of new molecularly-defined tumor types with prognostic and therapeutic implications. Methylation profiles, whole genome sequencing, and transcriptomics have defined subgroups and revealed heterogeneity within commonly defined tumor entities2,3. These findings have also revealed important differences between adult and pediatric brain tumors of similar histology. The majority of pediatric low grade gliomas (pLGG) are defined by alterations in the mitogen-activated protein kinase (MAPK) pathway including BRAFV600E point mutation, K1AA1549-BRAF fusion, and FGFR1 alterations as opposed to IDH1/2 mutations and 1p/19q co-deletion seen more frequently in adult low grade gliomas4. These findings have led to targeted therapies, namely BRAF and MEK inhibitors, which are currently being evaluated in phase III clinical trials and may soon supplant chemotherapy as standard of care for pLGG's. While targeted therapy trials for pediatric brain tumors have had significant success, immunotherapy remains a challenge in a group of tumors with generally lower mutational burden compared to adult tumors and relatively "cold" immune microenvironment. Despite this, a wide array of immunotherapy trials including vaccine therapies, immune checkpoint blockade, chimeric antigen receptor (CAR) T cells, and viral therapies are on-going. Unique to pediatrics, multiple clinical trials have sought to answer the question of whether the most malignant pediatric brain tumors in the youngest patients can be successfully treated with high dose chemotherapy in lieu of radiation to avoid devastating long-term neurocognitive deficits. Due to the collaborative work of multiple pediatric neuro-oncology consortiums, the recent history of pediatric brain tumor research is one of efficient translation from bench to bedside in a rare group of tumors resulting in significant progress in the field. Here, advances in the areas of molecular characterization, targeted and immune-based therapies, and reduction in long term co-morbidities will be reviewed.

Targeting the RAS/MAPK pathway in children with glioma

Pediatric low-grade glioma in the era of molecular diagnostics

Targeted therapy for pediatric low-grade glioma

Molecular markers for pediatric low-grade glioma

Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors

Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine

Myeloid cells as potential targets for immunotherapy in pediatric gliomas

Novel therapies for pediatric low grade glioma

Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies

Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas

Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era

Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae

Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

Pediatric-type low-grade gliomas in adolescents and young adults—challenges and emerging paradigms

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update

CAR-based therapeutic targets in pediatric high-grade glioma

A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas

Current and future therapy for BRAF-mutant pediatric glioma

Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.

LGG-36. Analysis of BRAF-related Mutations in Pediatric Low-Grade Glioma

A longitudinal single-cell and spatial multiomic atlas of pediatric high-grade glioma